School of Life Sciences

Image of Shola Olafuyi

Shola Olafuyi

Assistant Professor, Faculty of Medicine & Health Sciences



I am a passionate and highly motivated academic with research expertise in physiologically based pharmacokinetics (PBPK). I aspire to mentor and inspire the next generations of scientist.

I completed my BPharm degree in Pharmacy from University of Lagos, Nigeria and proceeded to gain clinical pharmacy experience as a pharmacist at the Chevron Nigeria Limited Hospital in Lagos and Reddington Multispecialist Hospital in Lagos for about 3 years.

I have an MSc. clinical pharmacy degree from the University of Strathclyde, Glasgow and I did my MSc project in the area of pharmacokinetics under the supervision of Dr Alison Thomson.

I have a PhD degree in physiologically based pharmacokinetics from Aston University which was obtained under the supervision of Dr Raj S.K Badhan and Prof Michael Coleman. My research involved the development of physiologically based pharmacokinetic models for antimalarial drugs used in special populations and was aimed at assessment of the pharmacokinetics of antimalarials in these population groups with the focus of understanding the pharmacokinetics of antimalarials and optimisation of antimalarial medication therapy.

I joined University of Nottingham in 2019 as an Assistant Professor in Pharmacology.

Expertise Summary

Pharmacokinetics, pharmacodynamics, PBPK modelling in special populations.

Teaching Summary

I am passionate about research inspired teaching excellence. I am currently a fellow of the HEA and hope to climb up the ranks in the future.

I am passionate about utilising current technologies to enhance students learning experience and facilitating learning in ways that promotes students engagement with the contents being learnt.

Recent Publications

Future Research

  1. Utilising PBPK modelling and simulation techniques to better understand the pharmacokinetics of several anti-infective drugs in sub-Saharan Africa (precisely, Western Africa) and propose how current drug therapy might be optimised or how new drug therapies might be effectively used. This involves ethical retrieval and generation of human physiological/biochemical data from subjects and using these data to develop virtual patients via in silico tools and using available or generated drug data to carryout pharmacokinetic modelling and simulations. This is important because the impact of physiological variabilities like CYP enzymes and transport protein polymorphisms, food intake, weight and blood biochemistry on the pharmacokinetics of several anti-infective agents in this ethnic groups is not well understood.
  2. My PBPK modelling and simulation focuses on drugs used to treat tropical diseases like malaria and tuberculosis agents and drugs used to treat neglected tropical diseases. The patient groups of interest are young children (neonates and infants), older children and pregnant women.

School of Life Sciences

University of Nottingham
Medical School
Queen's Medical Centre
Nottingham NG7 2UH

Contact us